Entero Healthcare Solutions Ltd (ENTERO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Entero Healthcare Solutions Ltd on NSE and BSE, with an AI summary of each filing.
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Others (Uncategorized) · 05 Nov 2026, 3:41 am
Entero Healthcare Subsidiary Faces Rs 11.87 Crore Customer Default and Provisions Entire Amount Entero Healthcare Solutions disclosed that its wholly owned subsidiary, Vasavi Medicare Solutions, experienced a payment default of Rs 11.87 crore from customer M/s. S M Pharma. Due to recoverability risks, Vasavi has fully provisioned the entire outstanding amount of Rs 11.87 crore in its books, capping the maximum consolidated financial impact at the same amount. Vasavi is initiating legal proceedings against the partnership firm to recover the defaulted dues.
Investor Presentation on Unaudited Financial Results for the quarter and half year ended September 30, 2026
Investor Presentation · 05 Nov 2026, 3:32 am
Entero Healthcare Delivers Strong Q2FY27 Earnings with 78% YoY EBITDA Growth Entero Healthcare delivered strong Q2FY27 performance, with reported revenue growing 32.9% YoY to Rs. 2,087.1 Cr (34.7% LFL YoY), driven by 18.2% organic growth. Gross margin expanded 126 bps YoY to 11.5%, while EBITDA surged 78% YoY to Rs. 110.7 Cr, expanding margins by 135 bps YoY to 5.3%. PAT increased 66% YoY to Rs. 60.7 Cr. For H1FY27, revenue reached Rs. 4,027.6 Cr (+35% YoY) with PAT at Rs. 112.8 Cr. Annualized RoCE and RoE improved to 22.0% and 22.4%, respectively.
Entero Healthcare Solutions Limited has informed the Exchange regarding Grant of 49712 Options.
Outcome · 05 Nov 2026, 2:02 am
Grant of fresh 49,712 (Forty-Nine Thousand Seven Hundred Twelve) Employee Stock Options under the existing 'Entero Employee Stock Option Plan 2023'.
Others (Uncategorized) · 05 Nov 2026, 2:00 am
Entero Healthcare Reports Q2 FY27 Results and Approves Fresh ESOP Grant Entero Healthcare Solutions reported consolidated revenue from operations of Rs 20,870.75m for the quarter ended 30th Sep'26, up 32.9% YoY from Rs 15,709.48m. Consolidated net profit rose 65.96% YoY to Rs 607.42m against Rs 366.00m, with basic EPS reaching Rs 10.47. For H1 FY27, consolidated revenue stood at Rs 40,275.70m with a net profit of Rs 1,127.93m. Additionally, the Board noted the grant of 49,712 fresh employee stock options under its ESOP Plan 2023 at an exercise price of Rs 804 per share.
Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026
Financial Result · 05 Nov 2026, 1:57 am
Entero Healthcare Solutions Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 05 Nov 2026, 1:44 am
Entero Healthcare Solutions Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 20,871 (+32.9% YoY | +7.6% QoQ) ■ EBITDA: 1,107 (+78.3% YoY | +14.1% QoQ) ■ EBITDA Margin (%): 5.3 (+135 bps YoY | +30 bps QoQ) ■ PAT: 455 (+44.1% YoY | +19.3% QoQ) ■ EPS (INR): 10.5 (+44.1% YoY | +19.3% QoQ)
Outcome of Board Meeting held on November 04, 2026
Outcome · 05 Nov 2026, 1:36 am
Intimation of Earnings call on Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026
Intimation · 05 Nov 2026, 1:30 pm
Entero Healthcare Solutions Schedules Q2FY27 Earnings Call for 5th Nov'26 Entero Healthcare Solutions Limited will host an earnings conference call on 5th Nov'26 at 13:30 IST to discuss its unaudited financial results for the quarter and half-year ended 30th Sep'26. The call is hosted by DAM Capital Advisors Ltd and will feature senior management, including MD & CEO Prabhat Agrawal, Whole Time Director & COO Prem Sethi, Group CFO Dr. Balakrishnan Natesan Kaushik, and Head of IR Akanksha Gupta. Primary universal dial-in numbers include +91 22 6280 1384 and +91 22 7115 8285.
Entero Healthcare Solutions Limited has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 04 Nov 2026, 5:30 am
Entero Healthcare Solutions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve and take on record ....
Intimation · 04 Nov 2026, 5:30 am
Entero Healthcare Solutions Schedules Board Meeting for Q2 Results on 4th Nov'26 Entero Healthcare Solutions Limited has scheduled a Board of Directors meeting on 4th Nov'26 to consider, approve, and record its unaudited standalone and consolidated financial results, along with the limited review report, for the quarter ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company securities has been closed for designated persons and their immediate relatives from 1st Oct'26 and will remain closed until 48 hours after the declaration of the financial results.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 04 Nov 2026, 5:30 am
Intimation of allotment of Equity Shares upon exercise of stock options under the Entero Employee Stock Option Plan 2023
Others (Uncategorized) · 13 Oct 2026, 2:21 am
Entero Healthcare Solutions Approves Equity Share Allotment Under ESOP 2023 Entero Healthcare Solutions Limited's Board approved the allotment of 43,155 equity shares (face value Rs. 10 each) on 12th Oct'26 following the exercise of vested options under ESOP Plan 2023. The issuance comprises 19,155 shares at an exercise price of Rs. 804 per share (Rs. 794 premium) and 24,000 shares at Rs. 1,124 per share (Rs. 1,114 premium). Post-allotment, the company's total issued share capital expands to Rs. 43,56,62,270, represented by 4,35,66,227 equity shares ranking pari-passu with existing equity.
Intimation of Schedule of Analyst/Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
Intimation · 22 Sept 2026, 5:47 pm
Entero Healthcare to Attend Arihant Capital Investor Conference Entero Healthcare Solutions Limited announced that its officials will participate in a virtual group investor conference organized by Arihant Capital Markets Ltd. on 29th Sep'26, starting from 02:00 P.M. onwards. The company confirmed that discussions will rely exclusively on publicly available information, with no unpublished price-sensitive information (UPSI) to be shared during the interaction.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Surbhi Singh - Prasid Uno Family Trust
Acquisition/ Disposal of Shares · 22 Sept 2026, 5:20 pm
Prasid Uno Family Trust Sells 4.89% Stake in Entero Healthcare Solutions Prasid Uno Family Trust (through Trustee Surbhi Singh) offloaded 21,30,000 equity shares (4.89% stake; 4.87% diluted) in Entero Healthcare Solutions Ltd via stock exchange deals. The disposal comprised 7,40,000 shares sold via Bulk Deal on 17th Sep'26 and 13,90,000 shares via Block Deal on 18th Sep'26. Consequently, the non-promoter trust’s total holding decreased from 7.94% (34,55,420 shares, including 1.24% encumbered) to 3.05% (13,25,420 shares, including 1.24% encumbered), leaving directly held voting shares at 1.81% (7,84,920 shares).
Entero Healthcare Solutions Limited has informed the Exchange about General Updates
Others (Uncategorized) · 13 Sept 2026, 12:59 am
GST Penalty Imposed on Entero Healthcare Subsidiary ACE Cardiopathy GST Authority, Office of Assistant Commissioner (Uttar Pradesh), levied a monetary penalty of Rs. 12,91,728 on ACE Cardiopathy Solutions Private Limited, a subsidiary of Entero Healthcare Solutions Limited, for non-generation of an E-Invoice. The order was received on 11th Sep'26. The penalty was paid under protest to secure immediate vehicle release and prevent demurrage or operational disruption. Entero confirmed the penalty is immaterial to consolidated financial performance and operations, with ACE Cardiopathy planning legal remedies to seek a refund.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Surbhi Singh Prasid Uno Family Trust
Acquisition/ Disposal of Shares · 26 Aug 2026, 10:45 pm
Prasid Uno Family Trust Increases Stake in Entero Healthcare Solutions Surbhi Singh of Prasid Uno Family Trust acquired 1,088,500 shares (2.49% of diluted capital) of Entero Healthcare Solutions Ltd on 24-Aug-26. The acquisition was made via a block deal. This transaction increased the trust's total holding of shares with voting rights to 3,014,920, representing 6.90% of the diluted share capital, up from 4.29% previously. The total holding, including encumbered shares, now stands at 7.91% of diluted capital, a decrease from the pre-acquisition total holding of 10.40% due to a release of encumbered shares.
Intimation of Schedule of Analyst/Institutional Investor meetings
Intimation · 25 Aug 2026, 1:28 am
Entero Healthcare Schedules Investor Meeting with Elara Capital Entero Healthcare Solutions has scheduled an analyst and institutional investor meeting for Sep 02, 2026. The 1x1/group meeting, organized by Elara Capital, will be held physically in Mumbai starting at 3:00 PM. Discussions will be based on publicly available information, with no unpublished price-sensitive information (UPSI) intended to be discussed. The company noted that the schedule is subject to change.
Completion of tenure of Mr. Rajesh Shashikant Dalal
Change in Management · 25 Aug 2026, 1:08 am
Entero Healthcare: Non-Executive Independent Director's Tenure Concludes Mr. Rajesh Shashikant Dalal's tenure as a Non-Executive Independent Director of Entero Healthcare Solutions Limited concluded on 24 Aug'26. Consequently, he has ceased to be the Chairperson of the Nomination and Remuneration Committee and the Stakeholders Relationship Committee. He also steps down as a member of the Audit Committee, effective from the same date. The change is due to the completion of his term of appointment.
Voting Results along with copy of Scrutinizer''s Report
Annual General Meeting · 20 Aug 2026, 12:45 am
Entero Healthcare AGM: All Resolutions Passed, Including Key Management Remuneration At its 8th AGM on Aug 19, '26, Entero Healthcare passed all resolutions with the requisite majority. Key approvals included adopting FY26 standalone and consolidated financial statements. Shareholders also approved special resolutions for the remuneration of CEO Prabhat Agrawal and COO Prem Sethi, passed with 93.58% and 93.95% of votes in favour, respectively. Re-appointments of Non-Executive Independent Directors Mr. Sujesh Vasudevan and Ms. Sandhya Gadkari Sharma were also approved, each securing over 94% favourable votes. All resolutions were passed through remote e-voting.
Proceedings of Annual General Meeting held on Wednesday, August 19, 2026.
Annual General Meeting · 20 Aug 2026, 12:42 am
Transcript of Earnings Call / Conference Call
Transcript · 17 Aug 2026, 7:09 pm
Recording of Earnings Call/ Conference Call on Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Audio / Video · 11 Aug 2026, 12:19 am
Entero Healthcare: Audio Recording of Q1FY27 Earnings Call Published Entero Healthcare Solutions has uploaded the audio recording of its analyst and investor conference call held to discuss unaudited financial results for the quarter ended 30 Jun'26. The company confirmed via a filing on 10 Aug'26 that the recording is now available on its website. A transcript of the call will be shared with the stock exchanges and uploaded to the company website in due course.
Investor Presentation on Unaudited Financial Results for the Quarter ended June 30, 2026
Investor Presentation · 08 Aug 2026, 12:54 am
Entero Healthcare Q1FY27: Strong Revenue Growth and Significant Margin Expansion Entero Healthcare reported strong Q1FY27 results with revenue up 38.2% YoY to INR 1,940 Cr, driven by 17.8% organic and 20.4% inorganic growth. Like-for-like revenue grew 40.0% YoY. EBITDA margin expanded 143bps YoY to 5.0%, while PAT margin increased to 2.7% from 2.2%. Return ratios improved significantly, with ROCE nearly doubling to 21.0% and ROE rising to 20.4%. Operational efficiency gained as net working capital days improved to 61 from 66 in Q1FY26. No new acquisitions were made during the quarter.
Unaudited Financial Results for the Quarter ended June 30, 2026.
Financial Result · 07 Aug 2026, 11:47 pm
Entero Healthcare Q1'27 Results: Strong YoY Growth, QoQ Profit Decline Entero Healthcare reported consolidated results for Q1 ended 30 Jun'26. Revenue from operations grew 38.2% YoY to ₹19,405 million. Net profit rose 72.2% YoY to ₹520.5 million but fell sequentially by 15.3% QoQ from ₹451.3 million (adjusted balancing figure for Q4'26 was ₹451.3m, but PAT for Q1'27 was ₹520.5m, making the comparison to previous quarter profit of ₹451.3m invalid. Instead, I should use the reported Q4'26 profit for comparison. The document shows Q4'26 profit as a balancing figure, but I will use the actual numbers provided. Q4'26 PAT was ₹451.28m, Q1'27 PAT is ₹520.51m. This is a QoQ *increase*, not a decline. Let's re-verify the numbers. Q1FY27 (30 Jun 26) PAT is 520.51m. Q4FY26 (31 Mar 26) PAT is 451.28m. So it's a QoQ increase. Let me rephrase. Okay, it seems I made a mistake in my initial calculation. The profit did not decline QoQ. Let's stick to the facts. Profit for Q1'27 is 520.51 million. Profit for Q4'26 is 451.28 million. So, profit increased QoQ. Let me re-write the summary based on this correct understanding. Okay, new plan for summary. 1. Headline numbers: Revenue YoY growth. 2. Profitability: PAT YoY growth and PAT QoQ growth. 3. Mention board changes. 4. Keep it under 90 words. New Summary Draft: Entero Healthcare reported consolidated results for Q1 ended 30 Jun'26. Revenue grew 38.2% YoY to ₹19,405 million. Profit After Tax rose significantly by 72.2% YoY to ₹520.5 million and also increased 15.3% QoQ. The Board also approved the reconstitution of its Audit, Nomination, and Stakeholders committees effective 25 Aug'26, following the tenure completion of a Non-Executive Independent Director. Standalone profit for the quarter was ₹34.6 million. Trading window opens 48 hours after results disclosure. Word count: 79. This works. It's accurate and covers the key points. The standalone profit is much smaller and might confuse things. Let's focus on the consolidated, which is more important for an equity analyst. Revised Summary Draft 2: Entero Healthcare reported strong consolidated results for Q1 ended 30 Jun'26. Revenue grew 38.2% YoY to ₹19,405 million, while Profit After Tax surged 72.2% YoY to ₹520.5 million. On a sequential basis, PAT also increased 15.3% QoQ. The Board approved the reconstitution of key committees, including Audit and Nomination, effective 25 Aug'26 following the tenure completion of a Non-Executive Independent Director. The trading window will open 48 hours after results disclosure. Word count: 77. This is better. It's focused, has the right metrics, and mentions the governance change. Final Check: - Title: Short, crisp, bold. Entero Healthcare Q1'27: Strong YoY Growth in Revenue and Profit (10 words). Good. - Summary: Under 90 words (77 words). One paragraph. No line breaks. Key info prioritized (YoY growth, PAT, governance). Succinct language. Accurate financial data. Shortened dates. YoY/QoQ used. No intro/outro. Direct and factual. All requirements met. - Output Structure: Follows the `[Title]` then `[Summary]` format. Looks good to go. I will use the final revised summary. Entero Healthcare Q1'27: Strong YoY Growth in Revenue and Profit Entero Healthcare reported strong consolidated results for Q1 ended 30 Jun'26. Revenue from operations grew 38.2% YoY to ₹19,405 million, while Profit After Tax surged 72.2% YoY to ₹520.5 million. On a sequential basis, PAT also increased 15.3% QoQ. The Board approved the reconstitution of key committees, including Audit and Nomination, effective 25 Aug'26 following the tenure completion of a Non-Executive Independent Director. The trading window opens 48 hours after results disclosure.
Outcome of Board Meeting held on August 07, 2026
Outcome · 07 Aug 2026, 11:23 pm
Entero Healthcare Solutions Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 19,405 (+38.2% YoY | +1.6% QoQ) ■ EBITDA: 970 (+93.7% YoY | +12.7% QoQ) ■ EBITDA Margin (%): 5.0 (+143 bps YoY | +49 bps QoQ) ■ PAT: 382 (+37.3% YoY | +36.2% QoQ) ■ EPS (INR): 8.76 (+37.3% YoY | +36.2% QoQ)